The financial performance of the Company for the Financial Year ended on 31^st March, 2025 is summarized as below:

(Rs. in Lakhs)

Total revenue for Financial Year 2024-25 is Rs. 85482.18 Lakhs compared to the total revenue of Rs. 406.17 Lakhs of previous Financial Year. The Company has incurred Profit before tax for the Financial Year 2024-25 of Rs. 1002.93 Lakhs as compared to Profit before tax of Rs. 7.36 Lakhs of previous Financial Year. Net Profit after Tax for the Financial Year 2024-25 is Rs. 751.93 Lakhs as against Net Profit after tax of Rs. 5.31 Lakhs of previous Financial Year. The Directors are continuously looking for the new avenues for future growth of the Company and expect more growth in the future period.

During the year under review, the company has changed its segment from Pharmaceuticals Trading to Trading in Agriculture activities.

During the year under review, The Company has increased the Authorised Share Capital from the existing Rs. 1.40,00,00,000/ - (Rupees One Hundred and Forty Crores Only) divided into 70,00,00,000 (Seventy Crores) Equity Shares of Rs. 2.00/- (Rupees Two Only) each to Rs. 1,90,00,00,000/- (Rupees One Hundred and Ninety Crores Only) divided into 95,00,00,000 (Ninety-Five Crores) Equity Shares of Rs. 2.00/- (Rupees Two Only) each ranking pari passu in all respect with the Existing Equity Shares of the Company in Extra Ordinary General Meeting held on 10^th January, 2025.

After the Clouser of Financial Year, The Company has approved Split/ Sub-division of Equity Shares of the Company from face value of Rs. 2.00/- (Rupees Two Only) each to face value of Re. 1.00/- (Rupee One Only) each through the Postal Ballot Commence on 30^th April, 2025 and ended on 29^th May, 2025

The authorized share capital of the Company as on 31^st March, 2025 is 1,90,00,00,000/- (Rupees One Hundred and Ninety Crores Only) divided into 95,00,00,000 (Ninety-Five Crores) Equity Shares of Rs. 2.00/- (Rupees Two Only)

B. Paid-up share capital:

During the year the Company has allotted 44,99,99,998 (Forty-Four Crores Ninety-Nine Lakhs Ninety-Nine Thousand Nine Hundred and Ninety-Eight) Equity shares pursuant to conversion of warrants into Equity shares on Preferential basis having face value of Rs. 2.00/- (Rupees Two Only) each, at an issue price of Rs. 2.02/- (Rupees Two and Twenty Paisa Only) per share (including Premium of Rs. 0.20/- {Rupee Twenty Paisa Only} per share) in the Board Meeting held on 24^th August, 2024.

During the year the Rights Issue Committee of Directors of the Company has allotted 23,23,70,539 (Twenty-three Crores Twenty-three Lakhs Seventy Thousand Five Hundred and Thirty-nine) Equity shares on Right basis having face value of Rs. 2.00/- (Rupees Two Only) each, at an issue price of Rs. 2.00/- (Rupees Two Only) per share in their Meeting held on 17th January, 2025.

The paid-up share capital of the Company as on 31^st March, 2025 is Rs. 1,85,89,64,310/- (Rupees One Hundred Eighty-Five Crores Eighty-nine Lakhs Sixty-four Thousand Three Hundred and Ten Only) divided into 1,85,89,64,310 (One Hundred Eighty-Five Crores Eighty-nine Lakhs Sixty-four Thousand Three Hundred and Ten) divided into 92,94,82,155 (Ninety-Two Crores Ninety Four Lakhs Eighty Two Thousand One Hundred and Fifty Five ) Equity Shares of Rs. 2.00/- (Rupees Two Only)

After the Clouser of Financial Year, Company has Issue of bonus shares in the ratio of 1:10 i.e., 1(One) new fully paid-up equity share of 1/- (Rupee One Only) each for every 10 (Ten) existing fully paid-up equity share of 1/- (Rupee One Only) each through the Postal Ballot Commence on 24^th June, 2025 and ended on 23^rd July, 2025

To conserve the resources for future prospect and growth of the Company, your Directors do not recommend any dividend for the Financial Year 2024-25 (Previous year - Nil).

Pursuant to Section 124 of the Companies Act, 2013, the amount of dividend remaining unpaid or unclaimed for a period of seven years shall be transferred to the Investor Education and Protection Fund (“IEPF”). During the year under review, there was no unpaid or unclaimed dividend in the “Unpaid Dividend Account” lying for a period of seven years from the date of transfer of such unpaid dividend to the said account. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund.

The profit of the Company for the Financial Year ending on 31^st March, 2025 is transferred to profit and loss account of the Company under Reserves and Surplus.

Pursuant to Section 92(3) read with Section134(3)(a) of the Act, the Annual Return as on March 31, 2025 is available on the Company's website at www.earumpharma.com.

Approval of Split/ Sub-division of Equity Shares:

The Company has approved Split/ Sub-division of Equity Shares of the Company from face value of Rs. 2.00/- each to face value of Re. 1.00/- each in the Extra-ordinary General Meeting held on 30^th May, 2025, and Stock exchange has approved on 11^th June, 2025 and Trading of Equity Shares has been resumed w.e.f. 11^th June, 2025. Consequently, altered the Authorised Share Capital and Paid-up Share Capital in the following manner:

A. The authorized share capital of the Company is Rs. 1,90,00,00,000/- (Rupees One Hundred and Ninety Crores Only) divided into 1,90,00,00,000 (One Hundred and Ninety Crores) Equity Shares of Rs. 1.00/- (Rupee One Only) each.

B. The Paid-up Share Capital of the Company is Rs. 1,85,89,64,310/- (Rupees One Hundred Eighty-Five Crores Eighty-nine Lakhs Sixty-four Thousand Three Hundred and Ten Only) divided into 1,85,89,64,310 (One Hundred Eighty-Five Crores Eighty-nine Lakhs Sixty-four Thousand Three Hundred and Ten) equity shares of Re. 1.00/- (Rupee One Only) each.

Allotment of Equity Shares on Preferential basis:

During the year, on 24^th August, 2025, the company, vide its Board Meeting, had allotted 44,99,99,998 (Forty-four Crore Ninety-nine Lakhs Ninety-nine Thousand Nine Hundred and Ninety-eight) fully paid-up equity shares of face value Rs. 2 (Rupees Two Only) each per equity share, at a price of Rs. 2.20/- (Rupees Two and Twenty Paisa Only) per equity share (at Premium), aggregating to Rs. 98,99,99,996 (Ninety-eight Crore Ninety-nine Lakhs Ninety-nine Thousand Nine Hundred and Ninety-six Only).

Consequently, the paid-up equity share capital of the Company had increased from Rs. 49,42,23,236 (Forty-nine Crores Forty-two Lakhs Twenty-three Thousand Two Hundred and Thirty-six Only) to Rs. 1,39,42,23,232/- (Rupees One Hundred Thirty-nine Crores Forty-two Lakhs Twenty-three Thousand Two Hundred and Thirty-two Only).

Allotment of Equity shares on Rights basis:

During the year, on 17^th January, 2025, the company, vide its Board Meeting, had allotted 23,23,70,539 (Twenty-three Crores Twenty-three Lakhs Seventy Thousand Five Hundred and Thirty-nine) fully paid-up equity shares of face value Rs. 2.00/- (Rupees Two Only) each per equity share, at a price of Rs. 2.00/- (Rupees Two Only) per equity share (at Par), aggregating to Rs. 46,47,41,078 (Forty-six Crores Forty-seven Lakhs Forty-one Thousand and Seventy-eight Only).

Consequently, the paid-up equity share capital of the Company had increased from Rs. 1,39,42,23,232/- (Rupees One Hundred Thirty-nine Crores Forty-two Lakhs Twenty-three Thousand Two Hundred and Thirty-two Only) to Rs. 1,85,89,64,310/- (Rupees One Hundred Eighty-Five Crores Eighty-nine Lakhs Sixty-four Thousand Three Hundred and Ten Only).

Allotment of Equity shares on Bonus basis

After the Clouser of Financial Year, Company has Issue of bonus shares in the ratio of 1:10 i.e., 1(One) new fully paid-up equity share of 1/- (Rupee One Only) each for every 10 (Ten) existing fully paid-up equity share of 1/- (Rupee One Only) each through the Postal Ballot Commence on 24^th June, 2025 and ended on 23^rd July, 2025

10. SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR

TRIBUNALS:

There are no significant material orders passed by the Regulators or Courts or Tribunal, which would impact the going concern status of the Company and its future operation.

11. MEETINGS OF THE BOARD OF DIRECTORS:

The Directors of the Company met at regular intervals at least once in a quarter with the gap between two meetings not exceeding 120 days to take a view of the Company's policies and strategies apart from the Board Matters.

During the year under the review, the Board of Directors met 20 (Twenty) times viz. 4^th April, 2024, 29^th May, 2024, 30^th May, 2024, 29^th June, 2024, 5^th July, 2024, 8^th July, 2024, 19^th July, 2024, 12^th August, 2024, 13^th August, 2024, 24^th August, 2024, 7^th September, 2024, 15^th October, 2024, 9^th November, 2024, 14^th November, 2024, 13^th December, 2024, 20^th December, 2024, 17^th January, 2025, 28^th January, 2025, 13^th February, 2025, 29^th March, 2025.

12. DIRECTORS RESPONSIBILITY STATEMENT:

In accordance with the provisions of Section 134 (3)(c) and Section 134(5) of the Companies Act, 2013, to the best of their knowledge and belief the Board of Directors hereby submit that:

a. In the preparation of the Annual Accounts, for the year ended on 31^st March, 2025 the applicable accounting standards have been followed and there is no material departure from the same; b. The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of financial year and of the profit of the Company for the financial year ended on 31^st March, 2025. c. The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities; d. The Directors had prepared the Annual Accounts on a going concern basis; e. The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and f. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

13. CORPORATE SOCIAL RESPONSIBILITY (CSR):

During the year the Company is covered under the criteria of the provision of Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, and therefore it is mandatory to comply with the same.

The Company has formed the CSR Committee as per the Section 135 of the Companies Act, 2013. On recommendation of CSR Committee, the Board of Directors of the Company has approved the CSR Policy which is available on the website of the Company i.e. www.earumpharma.com.

14. STATUTORY AUDITOR AND AUDITOR'S REPORT:

The Members of the Company at the Extra-ordinary General Meeting held on 10^th January, 2025, approved the appointment of M/s. Parin Patwari & Co., Chartered Accountants (FRN: 154571W) as the Statutory Auditors of the Company for the Financial Year 2024-25. The report issued by Statutory Auditors for financial year 2024-25 does not contain any qualifications or adverse remarks.

15. EXPLANATIONS / COMMENTS BY THE BOARD ON EVERY QUALIFICATION, RESERVATION OR

ADVERSE REMARK OR DISCLAIMER MADE:

i. Auditor's Report:

The statutory Auditor of the Company has included the following qualifications in their Audit Report for the Financial Year 2024-2025:

Reply:

The unsecured loans amounting to Rs. 21,275.11 Lakhs have been availed purely for meeting the business and operational requirements of the Company. These borrowings have been extended by related parties/associates for supporting the overall business activities without any expectation of interest. Hence, the nature of these loans is interest-free and no interest has been charged or accrued in the books of accounts.

It may further be noted that the Company has neither incurred any obligation to pay interest nor entered into any arrangement for such payments in respect of these loans. The management has ensured that the classification and presentation of these borrowings under unsecured loans is accurate and in accordance with the applicable accounting standards and statutory requirements.

The relevant agreements and supporting documents with respect to these loans have already been compiled and forwarded to our Chartered Accountant for their verification, review, and record-keeping purposes. This step has been taken to ensure transparency and compliance in the reporting of these liabilities.

Accordingly, the balances reflected in the financial statements are correct, and the interest-free status of these unsecured loans stands duly substantiated. The Company is committed to maintaining proper documentation and ensuring that all such transactions are fairly presented in the books of accounts.

Reply:

With respect to the observation regarding the balance of GST credit payable of Rs. 236.64 Lakhs, we would like to clarify that at the time of audit review, the reconciliation process with the GST online portal was under progress. Consequently, certain differences were appearing temporarily between the books of accounts and the portal figures.

Subsequently, a detailed reconciliation exercise has been carried out, covering all relevant input credits, outward liabilities, and adjustments. After completing this process, we confirm that the GST credit balances as per the company's books are now fully aligned with the balances reflected on the GST portal.

Hence, there is no mismatch in the records, and the company's claim of GST input credit as well as the liability towards the Government stands true and fairly presented in the financial statements.

Reply:

With reference to the observation regarding trade payables amounting to Rs. 19502.20 Lakhs and the bifurcation of creditors under the Micro, Small and Medium Enterprises Development (MSMED) Act, 2006, we wish to clarify that at the time of audit, the classification details from the respective vendors were not fully available. Since the confirmation of MSME status is dependent on declarations and registrations furnished by suppliers, there was a delay in obtaining the same from certain parties.

The management has already initiated the process of collecting the necessary MSME declarations/registrations from all vendors to ensure proper classification between MSME and non-MSME creditors. Once such details are fully received and verified, the same will be appropriately disclosed in the financial statements in compliance with the provisions of the

MSMED Act, 2006.

We further confirm that the Company is committed to full regulatory compliance and financial transparency. The matter is being given due priority, and future disclosures will contain the requisite bifurcation of trade payables into MSME and non-MSME categories in accordance with statutory requirements.

Reply:

With reference to the observation regarding advances to suppliers amounting to Rs. 6775.68 Lakhs, we would like to clarify that at the time of audit, the process of obtaining balance confirmations and execution of formal agreements with certain suppliers was pending. As a result, confirmations could not be obtained and submitted during the audit review.

However, the advances have been made in the normal course of business towards procurement of goods and services, and the same are duly supported by underlying transactions, purchase orders, and other documentary evidence available with the Company. The management is in continuous follow-up with the concerned suppliers to obtain written confirmations and agreements to ensure completeness of records.

We further confirm that these advances are genuine business transactions, appropriately recorded in the books of accounts, and there is no misstatement in the liabilities disclosed in the financial statements. The Company is committed to strengthening its documentation process and ensuring that all supplier confirmations are obtained on a timely basis in future.

Reply:

With reference to the observation regarding loans/advances amounting to Rs. 28,367.23 Lakhs remaining unconfirmed, we would like to clarify that at the time of audit, the process of obtaining confirmations from certain parties was still pending. Due to this, the confirmations could not be presented during the course of audit.

However, we confirm that these loans/advances have been granted in the ordinary course of business and are duly supported by the underlying records, agreements, and relevant documentation available with the Company. The balances have been correctly recorded in the books of accounts, and there is no misstatement in their presentation.

The management is in regular follow-up with the concerned parties to obtain written confirmations in order to further strengthen the documentation and compliance process. We assure that necessary steps are being taken to ensure timely confirmations in the future, thereby enhancing the reliability of financial disclosures.

Reply:

The Company is engaged purely in trading activities wherein goods are directly supplied by our suppliers to the customers. Accordingly, the Company does not maintain any stock in hand nor require ownership/lease of any godown or warehouse facilities. This business model is based on “direct dispatch” from supplier to customer, which eliminates the need for physical storage of inventory by the Company.

Further, contrary to the observation, the Company has already provided to the auditors all available supporting documents such as sales invoices, purchase invoices, and delivery notes evidencing the movement of goods. Since the transactions are on a direct-trading basis, separate Goods Inward Reports are not generated at the Company's end.

We reiterate that all trading transactions are genuine and duly supported by invoices and delivery documentation. The management remains committed to providing any additional supporting papers, wherever required, to substantiate the nature of operations and to ensure complete transparency in reporting.

Reply:

The Company is engaged purely in trading activities wherein goods are directly supplied by our suppliers to the customers. Accordingly, the Company does not maintain any stock in hand nor require ownership/lease of any godown or warehouse facilities. This business model is based on “direct dispatch” from supplier to customer, which eliminates the need for physical storage of inventory by the Company.

Further, contrary to the observation, the Company has already provided to the auditors all available supporting documents such as sales invoices, purchase invoices, and delivery notes evidencing the movement of goods. Since the transactions are on a direct-trading basis, separate Goods Inward Reports are not generated at the Company's end.

We reiterate that all trading transactions are genuine and duly supported by invoices and delivery documentation. The management remains committed to providing any additional supporting papers, wherever required, to substantiate the nature of operations and to ensure complete transparency in reporting.

Secretarial Auditor's Report:

Reply:

The Board clarifies that the newspaper advertisements for the mentioned financial periods were duly published. However, during cross-verification with the auditors, the copies were inadvertently misplaced. Efforts are underway to retrieve the archived copies from the publishers for record submission.

The Company is making efforts to retrieve the archived copies from the respective publication Houses and will submit them for record as soon as they are available.

Reply:

The Company has duly provided records demonstrating its compliance with the SDD requirements. Furthermore, the Company is in communication with the Exchange to resolve the said technical matter, and necessary steps are being taken to rectify the status at the earliest

Reply:

The Company has not accepted any deposits within the meaning of Section 73 to 76 of the Companies Act, 2013, or any other relevant provisions thereof. All funds reflected in the books pertain either to unsecured loans from directors, shareholders, or related parties, or trade advances in the normal course of business. Necessary management representations and supporting documents are available for verification.

16. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN, INVESTMENTS MADE AND SECURITIES

PROVIDED UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

The details of loans, investment, guarantees and securities covered under the provisions of section 186 of the Companies Act, 2013 are provided in the financial statement.

17. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

During the year under review, all the Related Party Transactions were entered at arm's length basis and in the ordinary course of business and were in compliance with the applicable provisions of the Act and the Listing Regulations.

Pursuant to Section 188 of the Act read with rules made thereunder and Regulation 23 of the Listing Regulations, all Material Related Party Transactions (“material RPTs”) require prior approval of the shareholders of the Company vide ordinary resolution.

The Company has formulated and adopted a policy on dealing with related party transactions, in line with Regulation 23 of the Listing Regulations, which is available on the website of the Company at www.earumpharma.com.

As a part of the mandate under the Listing Regulations and the terms of reference, the Audit Committee undertakes quarterly review of related party transactions entered into by the Company with its related parties. Pursuant to Regulation 23 of Listing Regulations and Section 177 of the Act, the Audit Committee has granted omnibus approval in respect of transactions which are repetitive in nature, which may or may not be foreseen, not exceeding the limits specified thereunder. The transactions under the purview of omnibus approval are reviewed on quarterly basis by the Audit Committee. Pursuant to Regulation 23(9) of the Listing Regulations, your Company has filed the disclosures on Related Party Transactions in prescribed format with the Stock Exchanges.

18. INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The Company has in place adequate internal financial controls with reference to financial statement across the organization. The same is subject to review periodically by the internal audit cell for its effectiveness. During the financial year, such controls were tested and no reportable material weaknesses in the design or operations were observed. The Statutory Auditors of the Company also test the effectiveness of Internal Financial Controls in accordance with the requisite standards prescribed by ICAI. Their expressed opinion forms part of the Independent Auditor's report.

Internal Financial Controls are an integrated part of the risk management process, addressing financial and financial reporting risks. The internal financial controls have been documented, digitized and embedded in the business processes.

Assurance on the effectiveness of internal financial controls is obtained through management reviews, control self-assessment, continuous monitoring by functional experts. We believe that these systems provide reasonable assurance that our internal financial controls are designed effectively and are operating as intended.

During the year no reportable material weakness was observed.

19. RESERVES & SURPLUS:

20. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS

AND OUTGO:

The details of conservation of energy, technology absorption etc. as required to be given under section 134(3)(m) of the Companies Act 2013 read with the Companies (Accounts) Rules, 2014, is not given as the Company has not taken any major step to conserve the energy etc.

There were no foreign exchange earnings or outgo during the year under review.

21. DISCLOSURES RELATING TO HOLDING / SUBSIDIARY / ASSOCIATE COMPANY AND JOINT

VENTURES:

The Company does not have any Holding / Subsidiary/Associate Company and Joint Venture.

22. SECRETARIAL STANDARDS:

During the year under review, the Company has complied with the applicable Secretarial Standards issued by The Institute of Company Secretaries of India (ICSI). The Company has devised proper systems to ensure compliance with its provisions and is in compliance with the same.

23. STATEMENT ON ANNUAL EVALUATION MADE BY THE BOARD OF DIRECTORS:

The Board evaluated the effectiveness of its functioning, that of the Committees and of individual Directors, pursuant to the provisions of the Act and SEBI Listing Regulations. The Board sought the feedback of Directors on various parameters including:

Degree of fulfillment of key responsibilities towards stakeholders (by way of monitoring corporate governance practices, participation in the long-term strategic planning, etc.); Structure, composition, and role clarity of the Board and Committees; Extent of co-ordination and cohesiveness between the Board and its Committees; Effectiveness of the deliberations and process management; Board / Committee culture and dynamics; and Quality of relationship between Board Members and the Management.

The above criteria are broadly based on the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India on January 5, 2017.

The Chairman of the Board had one-on-one meetings with each Independent Director and the Chairman of NRC had one-on-one meetings with each Executive and Non-Executive, Non-Independent Directors. These meetings were intended to obtain Directors' inputs on effectiveness of the Board/ Committee processes.

In a separate meeting of Independent Directors, performance of Non-Independent Directors, the Board as a whole, and the Chairman of the Company was evaluated, taking into account the views of Executive Directors and Non-Executive Directors.

The Nomination and Remuneration Committee reviewed the performance of the individual directors and the Board as a whole.

In the Board meeting that followed the meeting of the independent directors and the meeting of Nomination and Remuneration Committee, the performance of the Board, its committees, and individual directors was discussed.

The evaluation process endorsed the Board Members' confidence in the ethical standards of the Company, the resilience of the Board and the Management in navigating the Company during challenging times, cohesiveness amongst the Board Members, constructive relationship between the Board and the Management, and the openness of the Management in sharing strategic information to enable Board Members to discharge their responsibilities and fiduciary duties.

The Board carried out an annual performance evaluation of its own performance and that of its committees and individual directors as per the formal mechanism for such evaluation adopted by the Board. The performance evaluation of all the Directors was carried out by the Nomination and Remuneration Committee.

The performance evaluation of the Chairman, the Non-Independent Directors and the Board as a whole was carried out by the Independent Directors. The exercise of performance evaluation was carried out through a structured evaluation process covering various aspects of the Board functioning such as composition of the Board & committees, experience & competencies, performance of specific duties & obligations, contribution at the meetings and otherwise, independent judgment, governance issues etc.

Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Board has carried out the annual performance evaluation of the Directors individually as well as evaluation of the working of the Board by way of individual feedback from directors.

The evaluation frameworks were the following key areas:

a) For Non-Executive & Independent Directors:

Knowledge Professional Conduct

Comply Secretarial Standard issued by ICSI Duties Role and functions

b) For Executive Directors:

Performance as leader

Evaluating Business Opportunity and analysis of Risk Reward Scenarios Key set investment goal Professional conduct and integrity Sharing of information with Board. Adherence applicable government law

The Directors expressed their satisfaction with the evaluation process.

24. MANAGING THE RISKS OF FRAUD, CORRUPTION AND UNETHICAL BUSINESS PRACTICES:

a) Vigil Mechanism / Whistle Blower Policy:

The Company has established vigil mechanism and framed whistle blower policy for Directors and employees to report concerns about unethical behavior, actual or suspected fraud or violation of Company's Code of Conduct or Ethics Policy.

b) Business Conduct Policy:

The Company has framed “Business Conduct Policy”. Every employee is required to review and sign the policy at the time of joining and an undertaking shall be given for adherence to the Policy. The objective of the Policy is to conduct the business in an honest, transparent and in an ethical manner. The policy provides for anti-bribery and avoidance of other corruption practices by the employees of the Company.

25. PARTICULARS OF EMPLOYEES:

The provisions of Rule 5(2) & (3) of the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 are not applicable to the Company as none of the Employees of the Company has received remuneration above the limits specified in the Rule 5(2) & (3) of the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 during the financial year 2024-25.

26. LOANS FROM DIRECTOR / RELATIVE OF DIRECTOR:

During the year under review, the Company has not entered into any materially significant related party transactions which may have potential conflict with the interest of the Company at large. Suitable disclosures as required are provided in AS-18 which is forming the part of the notes to financial statement.

27. DIRECTORS AND KEY MANAGERIALPERSONNEL:

The Directors and Key Managerial Personnel of the Company are summarized below as on date: